NCT05209295 2026-01-12
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
Bristol-Myers Squibb
AbbVie
Pfizer
AbbVie
Sumitomo Pharma America, Inc.
GlaxoSmithKline